Cargando…

Cell-Mediated Immunity Generated in Response to a Purified Inactivated Vaccine for Dengue Virus Type 1

Dengue is the most prevalent arboviral disease afflicting humans, and a vaccine appears to be the most rational means of control. Dengue vaccine development is in a critical phase, with the first vaccine licensed in some countries where dengue is endemic but demonstrating insufficient efficacy in im...

Descripción completa

Detalles Bibliográficos
Autores principales:	Friberg, Heather, Martinez, Luis J., Lin, Leyi, Blaylock, Jason M., De La Barrera, Rafael A., Rothman, Alan L., Putnak, J. Robert, Eckels, Kenneth H., Thomas, Stephen J., Jarman, Richard G., Currier, Jeffrey R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6977178/ https://www.ncbi.nlm.nih.gov/pubmed/31969476 http://dx.doi.org/10.1128/mSphere.00671-19

Ejemplares similares

Safety and Immunogenicity of a Dengue Virus Serotype-1 Purified-Inactivated Vaccine: Results of a Phase 1 Clinical Trial
por: Martinez, Luis Javier, et al.
Publicado: (2015)

Characterization of B-cell and T-cell responses to a tetravalent dengue purified inactivated vaccine in healthy adults
por: Friberg, Heather, et al.
Publicado: (2022)

An Adjuvanted, Tetravalent Dengue Virus Purified Inactivated Vaccine Candidate Induces Long-Lasting and Protective Antibody Responses Against Dengue Challenge in Rhesus Macaques
por: Fernandez, Stefan, et al.
Publicado: (2015)

Phase I Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults from Puerto Rico
por: Diaz, Clemente, et al.
Publicado: (2018)

Phase 1 Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults in the United States
por: Schmidt, Alexander C., et al.
Publicado: (2017)

Safety and Immunogenicity of an AS03(B)-Adjuvanted Inactivated Tetravalent Dengue Virus Vaccine Administered on Varying Schedules to Healthy U.S. Adults: A Phase 1/2 Randomized Study
por: Lin, Leyi, et al.
Publicado: (2020)

Recombinant Dengue 2 Virus NS3 Helicase Protein Enhances Antibody and T-Cell Response of Purified Inactivated Vaccine
por: Simmons, Monika, et al.
Publicado: (2016)

Safety and Immunogenicity of Different Formulations of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults from Puerto Rico: Final Results after 3 Years of Follow-Up from a Randomized, Placebo-Controlled Phase I Study
por: Diaz, Clemente, et al.
Publicado: (2020)

Immunological Assays used to Support Efficacy of Zika Virus Vaccines
por: Eckels, Kenneth H., et al.
Publicado: (2019)

Cell-mediated immune responses to different formulations of a live-attenuated tetravalent dengue vaccine candidate in subjects living in dengue endemic and non-endemic regions
por: Moris, Philippe, et al.
Publicado: (2019)

Assessing the Diversity and Stability of Cellular Immunity Generated in Response to the Candidate Live-Attenuated Dengue Virus Vaccine TAK-003
por: Waickman, Adam T., et al.
Publicado: (2019)

Dengue Virus Exposures Among Deployed U.S. Military Personnel
por: Hesse, Elisabeth M., et al.
Publicado: (2017)

Protective versus pathologic pre-exposure cytokine profiles in dengue virus infection
por: Friberg, Heather, et al.
Publicado: (2018)

Long-Term Safety and Immunogenicity of a Tetravalent Live-Attenuated Dengue Vaccine and Evaluation of a Booster Dose Administered to Healthy Thai Children
por: Watanaveeradej, Veerachai, et al.
Publicado: (2016)

A Phase II, Randomized, Safety and Immunogenicity Study of a Re-Derived, Live-Attenuated Dengue Virus Vaccine in Healthy Adults
por: Thomas, Stephen J., et al.
Publicado: (2013)

Pre-existing Immunity to Japanese Encephalitis Virus Alters CD4 T Cell Responses to Zika Virus Inactivated Vaccine
por: Lima, Noemia S., et al.
Publicado: (2021)

Longitudinal Analysis of Dengue Virus–Specific Memory T Cell Responses and Their Association With Clinical Outcome in Subsequent DENV Infection
por: Sanchez-Vargas, Luis Alberto, et al.
Publicado: (2021)

Route of inoculation and mosquito vector exposure modulate dengue virus replication kinetics and immune responses in rhesus macaques
por: McCracken, Michael K., et al.
Publicado: (2020)

Enhanced dengue vaccine virus replication and neutralizing antibody responses in immune primed rhesus macaques
por: McCracken, Michael K., et al.
Publicado: (2021)

Stochastic Model of the Adaptive Immune Response Predicts Disease Severity and Captures Enhanced Cross-Reactivity in Natural Dengue Infections
por: Nguyen, Hung D., et al.
Publicado: (2021)

Dengue virus downregulates TNFR1- and TLR3-stimulated NF-κB activation by targeting RIPK1
por: Udawatte, Darshika J., et al.
Publicado: (2022)

Impact of prior flavivirus immunity on Zika virus infection in rhesus macaques
por: McCracken, Michael K., et al.
Publicado: (2017)

Safety and Immunogenicity of a Rederived, Live-Attenuated Dengue Virus Vaccine in Healthy Adults Living in Thailand: A Randomized Trial
por: Watanaveeradej, Veerachai, et al.
Publicado: (2014)

Impact of prior Dengue immunity on Zika vaccine protection in rhesus macaques and mice
por: Larocca, Rafael A., et al.
Publicado: (2021)

Analysis of cell-associated DENV RNA by oligo(dT) primed 5’ capture scRNAseq
por: Sanborn, Mark A., et al.
Publicado: (2020)

Mapping of a region of dengue virus type-2 glycoprotein required for binding by a neutralizing monoclonal antibody
por: Trirawatanapong, Thaweesak, et al.
Publicado: (1992)

Dengue Virus Infection and Virus-Specific HLA-A2 Restricted Immune Responses in Humanized NOD-scid IL2rγ(null) Mice
por: Jaiswal, Smita, et al.
Publicado: (2009)

1051. Characterization of Immune Responses to a Live-Attenuated Tetravalent Dengue Vaccine
por: Braun, Ralph, et al.
Publicado: (2021)

Enhanced Immunogenicity of Inactivated Dengue Vaccines by Novel Polysaccharide-Based Adjuvants in Mice
por: Wu, Shuenn-Jue, et al.
Publicado: (2022)

Temporally integrated single cell RNA sequencing analysis of PBMC from experimental and natural primary human DENV-1 infections
por: Waickman, Adam T., et al.
Publicado: (2021)

Dissecting the heterogeneity of DENV vaccine-elicited cellular immunity using single-cell RNA sequencing and metabolic profiling
por: Waickman, Adam T., et al.
Publicado: (2019)

Purified Inactivated Zika Vaccine Candidates Afford Protection against Lethal Challenge in Mice
por: Baldwin, Whitney R., et al.
Publicado: (2018)

Monomeric IgA Antagonizes IgG-Mediated Enhancement of DENV Infection
por: Wegman, Adam D., et al.
Publicado: (2021)

Complete Protection in Macaques Conferred by Purified Inactivated Zika Vaccine: Defining a Correlate of Protection
por: Young, Ginger, et al.
Publicado: (2020)

The Inactivation by Organic Solvents and Detergents of Partially Purified Rous I Virus Preparations
por: Drayton, H. A.
Publicado: (1961)

Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine
por: Qin, Ede, et al.
Publicado: (2006)

Longitudinal Analysis of Memory B and T Cell Responses to Dengue Virus in a 5-Year Prospective Cohort Study in Thailand
por: Sánchez-Vargas, Luis A., et al.
Publicado: (2019)

Correlation between reported dengue illness history and seropositivity in rural Thailand
por: Buddhari, Darunee, et al.
Publicado: (2021)

Binding and inactivation of human coronaviruses, including SARS-CoV-2, onto purified clinoptilolite-tuff
por: Nizet, S., et al.
Publicado: (2023)

Serotype-Specific Differences in the Risk of Dengue Hemorrhagic Fever: An Analysis of Data Collected in Bangkok, Thailand from 1994 to 2006
por: Fried, Jessica R., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_oecuf18a86s4436s1uq4e423gg